A B S T R A C T Factor XIa is a plasma protease that, by activating Factor IX, plays an important role in the early phase of the intrinsic pathway of blood coagulation. Four plasma protease inhibitors, a1-protease inhibitor, antithrombin III, Cl-inhibitor, and a2-plasmin inhibitor, have been reported to inactivate human Factor XIa, but their quantitative contribution to the inactivation of Factor XIa in plasma has not been fully assessed. Using purified systems, we observed that the second-order rate constants for the reaction of Factor XIa with a1-protease inhibitor, antithrombin III, and Cl-inhibitor were 4.08, 10, and 14.6 M`min-' X 103, respectively. The pseudo-first-order rate constants, at plasma concentration of the inhibitors, were 1.86 X 10-1, 4.68 X 10-2, and 2.4 X 10-2 min-', respectively. These kinetic data predict that al-protease inhibitor should account for 68%, antithrombin III for 16%, and Cl-inhibitor and the equipotent a2-plasmin inhibitor each for 8% of the total inhibitory activity of plasma against Factor XIa. The rate of inactivation of Factor XIa in various plasma samples specifically deficient in inhibitors was consistent with these predictions.
XIa and the light chain derived from HMW kininogen. The protective effect of HMW kininogen was confirmed by the finding that the inactivation rate of Fac-INTRODUCTION Factor XII, prekallikrein, high molecular weight (HMW)' kininogen, and Factor XI are plasma proteins required for the in vitro initiation of blood coagulation induced by exposure to a foreign surface. Purified Factor XI, like prekallikrein, is converted to an active serine protease by activated Factor XII (1, 2) in the presence of the cofactor HMW kininogen (3) . Since Factor XIa is the first enzyme belonging primarily to the coagulation cascade, and since a hemorrhagic state can result from its deficiency, it may play a key role in the regulation of blood coagulation. The active enzymes in the contact system, Factor XIIa, kallikrein, and Factor XIa are subject to inactivation by several plasma protease inhibitors. In the case of Factor XIa, four different plasma proteins-Cl-inhibitor (4), antithrombin III (5), a1-protease inhibitor (a1-antitrypsin) (6) , and a2-antiplasmin (7)-have been found to have inhibitory activity, whereas another plasma protease inhibitor, a2-macroglobulin (8), does not inactivate Factor XIa. A quantitative comparison of the kinetics and potency of these inhibitors has not been made in purified systems and the relative contribution of each inhibitor to the inactivation of XIa in plasma is not known. The cofactor, HMW kininogen, must also be 'Abbreviations used in this paper: HMW, high molecular weight; HMWKL, light chain derived from HMW kininogen; LMW, light molecular weight. considered in evaluating the regulation of Factor XIa inhibition by plasma protease inhibitors. Factor XI, the zymogen of Factor XIa, prekallikrein, the precursor of plasma kallikrein, and plasma kallikrein, are each known to form a bimolecular complex with HMW kininogen (9) (10) (11) (12) . Furthermore, when plasma kallikrein forms a complex with HMW kininogen, a decrease in the inactivation rate by plasma protease inhibitors is observed (13) . Since HMW kininogen is capable of protecting kallikrein from inactivation, we explored the possibility that it could also protect Factor XIa. This study was designed to quantitate the relative contribution of the plasma protease inhibitors of Factor XIa, as well as to examine the effect of HMW kininogen on the inhibition of Factor XIa.
METHODS

Plasma
All plasma samples were collected from either healthy volunteers or factor-deficient donors into a 1/10 vol of 3 (17) . Plasma was rendered deficient in antithrombin III by passing the plasma over a heparin-agarose column equilibrated with 20 mM Tris Cl buffer, pH 7.5, containing 0.15 M NaCl (18 (24) .
Factor XI. This was prepared essentially according to the method of Scott et al. (27) for isolating prekallikrein. When the gamma globulins from plasma were subjected to SPSephadex chromatography at pH 8.1, the Factor XI bound more tightly than the prekallikrein (6, 25) . The Factor XIrich fractions were then pooled, concentrated, dialyzed, and applied to a second SP-Sephadex column, pH 5.3, identical to the column used for prekallikrein isolation (27) . The Factor XI-rich fractions from that column were then concentrated and dialyzed vs. 10 mM sodium acetate, pH 5.3, containing 0.15 M NaCl. The final step in the purification of Factor XI was the removal of immunoglobulin (Ig) G by batch adsorption to 1 ml of anti-IgG-agarose that had been equilibrated in 0.1 M Tris-Cl, pH 8.0, containing 0.15 M NaCl. Factor XI (0.4 ml of a stock of 90 U/ml) was diluted 1:2 with buffer and then mixed with the 1 ml of equilibrated gel in a microcentrifuge tube (1.5-ml capacity) for 5 Inhibition of Factor XIa. All incubations were performed in 0.5-ml polypropylene microcentrifuge tubes at 23 or 37°C. To minimize both the adsorption of Factor XIa onto the test tube surface and its consequent inactivation, bovine serum albumin (5 mg/ml) was incubated in the tube for 5 min. Next, Factor Xla was added and incubated for 5 min. HMW kininogen or buffer was then added, and, finally, inhibitor was added. At various times, 10 Ml was removed and assayed for Factor XIa activity as described above. The data are expressed as percentages of initial Factor XIa activity.
SDS slab gel electrophoresis. Samples were applied to 10% polyacrylamide gels (10 cm X 10 cm X 1.5 mm) according to either Laemmli (21) or Weber and Osborn (26) .
RESULTS
Purity of Factor XIa. 100 1l of radiolabeled Factor XIa, after removal of unbound radioactivity (see Methods), was chromatographed on a Bio-Rad A5M column in the presence of 0.1% SDS (Fig. 1) . One major peak of radioactivity was observed, eluting with a M, of 150,000. Factor XIa was also electrophoresed on a slab gel (20) in the presence of SDS without a reducing agent (Fig. 1, inset) . It A linear relationship was observed between the pseudofirst-order reaction rate constant, k', and inhibitor concentration (Fig. 2, insets) . Second-order rate constants (k") for the inhibition of XIa at 23°C were calculated from the insets of Fig. 2 and found to be 4,000 (alprotease inhibitor), 10,000 (antithrombin III), and 15,000 (Cl-inhibitor) M-l min-'. Effect of HMW kininogen on the inhibition of Factor XIa. Since HMW kininogen is known to form a complex with Factor XI, prekallikrein, and kallikrein in plasma (9-12), we tested the hypothesis that like kallikrein, Factor XI might be protected by HMW kininogen from inhibition. When various concentrations of HMW kininogen were added to Factor XIa at 23°C, before addition of inhibitor, the rate of inhibition was decreased in a concentration-dependent fashion when compared with the inactivation rate of Factor XIa in the absence of HMW kininogen (Fig.  3) . We assumed a model represented by the expression: Fig. 3 .
Effect of HMWKL on Factor XIa inhibition. HMWKL was added to Factor XIa before the addition of Cl-inhibitor at 23°C (Fig. 4) (I) . The values for k' were tabulated for a1-protease inhibitor, antithrombin III, and Cl-inhibitor from this study, and for a2-plasmin inhibitor from the report of Saito et al. (7) . From these data we predicted that al-protease inhibitor would be responsible for 68% of the inhibitory activity in plasma against Factor XIa. Antithrombin III was estimated to be responsible for 16%, and Cl-inhibitor and a2-plasmin inhibitor were each responsible for 8% of the total inhibitory activity against Factor XIa.
Although the rate of inhibition was increased approximately threefold at 370C, as compared to 230C, similar results were obtained for the relative contribution of inhibitors when the k' was calculated from data derived at either temperature (Table I ). In agreement with Harpel (8) nogen at a final dilution of plasma equal to 1:7.5 (Fig.  5) . HMW kininogen-deficient plasma exhibited a 20% increase in the inhibitory activity of normal plasma against Factor XIa under the conditions employed. a1-protease inhibitor-deficient plasma, which contained 20% of normal a1-protease activity, exhibited only 53% of the inhibitory capacity of normal plasma.~5 The antithrombin III-deficient plasma demonstrated 80% of normal inhibitory capacity. Cl-inhibitor-deficient plasma showed 95% of normal .activity and a2-plasmin-inhibitor-deficient plasma was virtually identical to normal plasma (Table II) . Therefore, a1-protease inhibitor is the major inhibitor of Factor XIa in (31) . § Pseudo-first-order reaction rate derived by multiplying the k' by [I] .
"From Saito et al. (7) . ¶ On the assumption that the k' is equal to the k' for Cl-inhibitor (7). The inhibitory activity was measured in plasma diluted 1:7.5 (see Fig. 6 ). 4 Normal pooled plasma used as a reference.
plasma, in agreement with the conclusions of Heck and Kaplan (6) . with the release of the peptide bradykinin (Mr = 1,500) from the heavy chain (24, 34) . Upon reduction, the two polypeptide chains are separated. LMW kininogen, which is antigenically similar to the heavy chain of HMW kininogen, and does not exhibit coagulant activity (35) , did not modulate the inhibition of Factor XIa. In contrast, the light chain, which contains the coagulant activity of HMW kininogen (24, 35) (35) and our present data may be due to either a higher affinity of HMW kininogen for the zymogens in that study than for the enzymes in our study. Alternatively, it may reflect the difference between functional kinetic determinations in the fluid-phase vs. physical binding measured in the presence of a plastic surface (36) . The affinity of the proteins itself for the surface especially at low concentrations (37) (38) .
DISCUSSION
The regulation of the inhibition of Factor XIa and kallikrein greatly differs. The second-order rate constant for the inhibition of Factor XIa by each of its plasma protease inhibitors is very similar. Therefore, it is only the concentration of each inhibitor in plasma that dictates which will be the most effective inhibitor of Factor XIa. This observation contrasts with the k" that was calculated for each inhibitor of kallikrein (38) . The reaction of kallikrein and Cl-inhibitor is 5,000-fold greater than the k" for the reaction of kallikrein and a1-protease inhibitor. In contrast, as previously observed (6), a1-protease inhibitor is the major inhibitor of Factor XIa. Quantitatively it accounts for 68% of the inhibitory activity of plasma, whereas Cl-inhibitor, a major inhibitor of kallikrein, accounts for only 8% of the inhibitory activity of Factor XIa. a2-macroglobulin, the other major inhibitor of kallikrein, does not inhibit Factor XIa. Although the k' for the inhibition of kallikrein by Cl-inhibitor, at plasma concentration of Cl-inhibitor, is 10 times greater than the k' for Factor XIa-a1-protease inhibitor complex at the plasma concentration of a1-protease inhibitor, HMW kininogen protects Factor XIa fourfold more effectively than it protects kallikrein against inactivation.
Antithrombin III accounts for 17% of the plasma inhibitory activity against Factor XIa. Damus et al. (5) have reported that heparin greatly accelerates the inactivation rate of Factor XIa by antithrombin III, suggesting the possibility that in the presence of heparin, antithrombin III might become the major inhibitor in plasma of Factor XIa. Since Busch and Owen (39) have recently found that the vascular endothelium catalyzes the thrombin-antithrombin III reaction in a manner analogous to free heparin; it is possible that the major inhibitor of Factor XIa in vivo is antithrombin III bound to the endothelium. However, we have recently demonstrated (40) using both amidolytic and coagulant assays in purified systems and plasma that heparin (1 U/ml) failed to accelerate the inactivation rate of Factor XIa while dramatically increasing the inhibition of thrombin. Thus, it appears unlikely that antithrombin III plays a major inhibitory role in plasma against Factor XIa.
Since both Factor XI and prekallikrein are activated by the same enzyme (Factor XIIa) in the presence of the same cofactor (HMW kininogen), it is clear that both the differential effect of plasma protease inhibitors on the two enzymes and the quantitative differences in the protection offered by HMW kininogen may serve as major regulators of these enzymes in plasma. Variations in enzyme, inhibitor, or HMW kininogen concentration may direct the contact system, after Factor XII activation, toward coagulation via Factor XIa, or toward fibrinolysis and vasodilation via kallikrein action.
Finally, a1-protease inhibitor is usually considered an inhibitor of tissue proteases such as elastase and trypsin. A role for this inhibitor in plasma, where it accounts for almost 5% of the total plasma protein, is not surprising. It is possible that in the familial deficiency of a1-protease inhibitor, or in the acquired deficiency of that inhibitor resulting from smoking cigarettes (41, 42) , the decrease of inhibition of Factor XIa could result in the localized fibrin formation that might play a role in the pulmonary diseases associated with this deficiency.
